Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
This study is intend to improve the progression-free survial of the recurrent
paltinum-resistant ovarian cancer. All the participants will receive camrelizumab combined
with apatinib.